胶质瘤
剧目
核糖核酸
癌症研究
计算生物学
基因
生物
遗传学
物理
声学
作者
Shawn Kothari,Anna C. Dusenbery,Abigail Doucette,Daniel Y. Zhang,Dominique Ballinger,Arati Desai,Jennifer J.D. Morrissette,Stephen Bagley,MacLean P. Nasrallah
出处
期刊:Neuro-Oncology Practice
[Oxford University Press]
日期:2023-04-14
卷期号:10 (4): 370-380
摘要
Abstract Background Recurrent gliomas are therapeutically challenging diseases with few treatment options available. One area of potential therapeutic vulnerability is the presence of targetable oncogenic fusion proteins. Methods To better understand the clinical benefit of routinely testing for fusion proteins in adult glioma patients, we performed a retrospective review of 647 adult patients with glioma who underwent surgical resection at our center between August 2017 and May 2021 and whose tumors were analyzed with an in-house fusion transcript panel. Results Fifty-two patients (8%) were found to harbor a potentially targetable fusion with 11 (21%) of these patients receiving treatment with a fusion-targeted inhibitor. The targetable genes found to be involved in a fusion included FGFR3, MET, EGFR, NTRK1, NTRK2, BRAF, ROS1, and PIK3CA. Conclusions This analysis demonstrates that routine clinical testing for gene fusions identifies a diverse repertoire of potential therapeutic targets in adult patients with glioma and can offer rational therapeutic options for patients with recurrent disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI